Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.

Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.

Abstract: Particles, useful as a delivery system for an epitope, are composed of a chimaeric hepadnavirus core antigen protein wherein a foreign amino acid sequence comprising an epitope is inserted in or replaces all or part of the sequence of amino acid residues from 68 to 90 in the case where the core antigen is hepatitis B core antigen or the corresponding amino acid sequence in the case of the core antigen of another hepadnavirus.

Abstract: Liposomes which have present on their surface a polypeptide capable of binding to a mucosal cell surface of a human or animal and which are substantially free of active neuraminidase are useful as vaccines.

Abstract: A stabilized immunoglobulin composition comprises at least one immunoglobulin together with a stabilizing amount of a chelator of copper ions such as EDTA or citrate. Preferably the immunoglobulin is an antibody, for example, a recombinant CDR-grafted antibody. A process for enhancing the stability of an immunoglobulin comprises subjecting the immunoglobulin to a purification procedure capable of removing copper ions therefrom. Preferably, the immunoglobulin is rendered substantially free from detectable copper ions as determined, for example, by atomic absorption spectroscopy.

Abstract: The invention concerns a vaccine comprising an attenuated Salmonella bacterium which contains a nirB promoter operably linked to a DNA sequence encoding a heterologous protein. The nirB promoter directs expression of the heterologous protein in a host it is wished to vaccinate.

Abstract: The present invention relates to indolopyrolocarbazole derivatives, to their use in methods of treatment or prophylaxis of at least one viral infection or cardiovascular diseases; and pharmaceutical formulations containing such derivatives.

Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.

Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.

Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.

Abstract: Antiviral nucleoside analogues contain a substituted benzimidazole base attached to a carbocyclic ring in place of the conventional sugar residue. Particularly preferred compounds include those in which the 2-, 5- and 6- positions of the benzimidazole base are substituted by halogen. The compounds have activity against herpes virus especially cytomegalovirus and also hepatitis B virus infections.

Abstract: A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.

Abstract: This invention relates to the use of a class of compounds as immunopotentiaters, compositions containing such compounds and their manufacture, combinations of such compounds with anti-tumor or anti-infective drugs and the use of such combinations in the prophylaxis or treatment of such diseases arising from tumors or infections.

Abstract: Disclosed herein is a sealed tamper-evident container. The container comprises: a bottle having a side wall portion and an open mouth portion; a cap connected to the bottle mouth portion; a frangible label connected to the bottle side wall portion; a wrapper having an upper portion that overlies the cap and a lower portion that overlies the bottle and at least a portion of the label so that the cap is sealably fixed to the bottle; and means for securing the wrapper lower portion with the frangible label. The wrapper upper portion is removable from the container and the cap so that the cap can be separated from the container. Removal of the wrapper lower portion ruptures the frangible label; the label rupture serves as a visible indicia of the removal of the wrapper bottom portion from the bottle, and thus alerts the consumer to possible tampering.

Abstract: 6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.

Abstract: A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.

Abstract: The present invention is concerned with the use of a compound of formula (I): Ar--Y--Q, wherein Ar is either (i) furyl, thienyl, thienyl 1,1-dioxide, pyrryl, pyridyl, benzofuryl, benzothienyl, benzothienyl 1,1-dioxide, indolyl, naphthyl, quinolyl, or tetrahydronaphthyl, any of which is optionally substituted by one or more substituents independently selected from C.sub.1-4 alkyl (which may itself optionally be substituted by one or more halogen atoms), C.sub.1-4 alkoxy, halo, nitro, amino, carboxy, C.sub.1-4 alkoxy-carbonyl and hydroxy, or (ii) phenyl optionally substituted by one or more substituents independently selected from phenyl (which is itself optionally substituted by one or more substituents independently selected from those optional substituents specified in (i) above) and those specified as optional substituents in (i) above, Y is C.sub.1-10 alkylene or C.sub.2-10 alkenylene; Q is formula (II), where R.sup.1 is hydrogen, C.sub.

Abstract: Indazoles of Formula (I) ##STR1## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each separately selected from hydrogen, halogeno, halogenoalkyl, formyl, carboxy, sulpho, cyano, nitro, COR and .sup.+ NRR'R" groups, wherein R, R' and R" are each separately alkyl, aralkyl or aryl groups, and R.sub.5 is selected from hydrogen, halogeno, halogenoalky, formyl, carboxy, sulpho, cyano, nitro, hydroxy, alkoxy, alkyl, COR, NHCOR and .sup.+ NRR'R" groups, wherein R, R' and R" are each separately alkyl, aralkyl or aryl groups, which may optionally be in the form of a physiologically acceptable ester or salt, are of value for use as an analgesic or in the treatment of any condition where the inhibition of brain/spinal cord nitric oxide synthase is advantageous, for example in neurodegenerative disease.